Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Antimicrobial Prophylaxis for Patients Undergoing Cardiac Surgery: Intraoperative Cefazolin Concentrations and Sternal Wound Infections.

Zelenitsky SA, Calic D, Arora RC, Grocott HP, Lakowski TM, Lillico R, Ariano RE.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01360-18. doi: 10.1128/AAC.01360-18. Print 2018 Nov.

PMID:
30150469
2.

Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass-authors' response.

Zelenitsky SA, Calic D, Ariano RE.

J Antimicrob Chemother. 2018 Sep 1;73(9):2588. doi: 10.1093/jac/dky249. No abstract available.

PMID:
29945163
3.

Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis.

Zelenitsky SA, Beahm NP, Iacovides H, Ariano RE, Zhanel G.

J Antimicrob Chemother. 2018 Jul 1;73(7):1888-1894. doi: 10.1093/jac/dky120.

PMID:
29635472
4.

Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass.

Calic D, Ariano RE, Arora RC, Grocott HP, Lakowski TM, Lillico R, Zelenitsky SA.

J Antimicrob Chemother. 2018 Mar 1;73(3):768-771. doi: 10.1093/jac/dkx439.

PMID:
29237016
5.

No role for patient body weight on renal function assessment for drug dosing.

Ariano RE, Zelenitsky SA, Poncsak KR, Davis JC, Vercaigne LM.

J Antimicrob Chemother. 2017 Jun 1;72(6):1802-1811. doi: 10.1093/jac/dkx036.

PMID:
28369383
6.

Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014.

Zelenitsky SA, Howarth J, Lagacé-Wiens P, Sathianathan C, Ariano R, Davis C, Verrelli M.

Perit Dial Int. 2017 Mar-Apr;37(2):170-176. doi: 10.3747/pdi.2016.00136. Epub 2016 Oct 13.

PMID:
27738087
7.

Integrated pharmacokinetic-pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery.

Zelenitsky SA, Lawson C, Calic D, Ariano RE, Roberts JA, Lipman J, Zhanel GG.

J Antimicrob Chemother. 2016 Oct;71(10):2902-8. doi: 10.1093/jac/dkw247. Epub 2016 Jul 7.

PMID:
27402005
8.

Successful treatment of pulmonary blastomycosis with continuously infused amphotericin B deoxycholate after failure with liposomal amphotericin B.

Ariano RE, Mitchelmore BR, Lagacé-Wiens PR, Zelenitsky SA.

Ann Pharmacother. 2013 Jun;47(6):e26. doi: 10.1345/aph.1R703. Epub 2013 May 14.

PMID:
23673538
9.

Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD).

Zelenitsky SA, Rubinstein E, Ariano RE, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i67-72. doi: 10.1093/jac/dkt028.

PMID:
23587780
10.

Initial vancomycin dosing protocol to achieve therapeutic serum concentrations in patients undergoing hemodialysis.

Zelenitsky SA, Ariano RE, McCrae ML, Vercaigne LM.

Clin Infect Dis. 2012 Aug;55(4):527-33. doi: 10.1093/cid/cis458. Epub 2012 May 9.

PMID:
22573855
11.

Optimization of meropenem dosage in the critically ill population based on renal function.

Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP.

Intensive Care Med. 2011 Apr;37(4):632-8. doi: 10.1007/s00134-010-2105-0. Epub 2010 Dec 7.

PMID:
21136037
12.

Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data.

Zelenitsky SA, Ariano RE, Zhanel GG.

J Antimicrob Chemother. 2011 Feb;66(2):343-9. doi: 10.1093/jac/dkq348. Epub 2010 Oct 5.

PMID:
20926397
13.

Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection.

Zelenitsky SA, Ariano RE.

J Antimicrob Chemother. 2010 Aug;65(8):1725-32. doi: 10.1093/jac/dkq211. Epub 2010 Jun 17.

PMID:
20558470
14.

Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.

Ariano RE, Sitar DS, Zelenitsky SA, Zarychanski R, Pisipati A, Ahern S, Kanji S, Rello J, Kumar A.

CMAJ. 2010 Mar 9;182(4):357-63. doi: 10.1503/cmaj.092127. Epub 2010 Feb 16.

15.

Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.

Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, Nicolau DP.

Antimicrob Agents Chemother. 2009 Apr;53(4):1476-81. doi: 10.1128/AAC.01141-08. Epub 2009 Feb 2.

16.

Aminoglycoside-induced vestibular injury: maintaining a sense of balance.

Ariano RE, Zelenitsky SA, Kassum DA.

Ann Pharmacother. 2008 Sep;42(9):1282-9. doi: 10.1345/aph.1L001. Epub 2008 Jul 22.

PMID:
18648019
17.

Effectiveness of a 30% ethanol/4% trisodium citrate locking solution in preventing biofilm formation by organisms causing haemodialysis catheter-related infections.

Takla TA, Zelenitsky SA, Vercaigne LM.

J Antimicrob Chemother. 2008 Nov;62(5):1024-6. doi: 10.1093/jac/dkn291. Epub 2008 Jul 18.

PMID:
18641034
18.

Effect of an ethanol/trisodium citrate hemodialysis catheter locking solution on isolates of Candida albicans.

Maharaj AR, Zelenitsky SA, Vercaigne LM.

Hemodial Int. 2008 Jul;12(3):342-7. doi: 10.1111/j.1542-4758.2008.00279.x.

PMID:
18638091
19.

Effect of ethanol/trisodium citrate lock on microorganisms causing hemodialysis catheter-related infections.

Takla TA, Zelenitsky SA, Vercaigne LM.

J Vasc Access. 2007 Oct-Dec;8(4):262-7.

PMID:
18161672
20.

Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis.

Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA.

Am J Kidney Dis. 2005 Oct;46(4):681-7.

PMID:
16183423
21.

An evaluation of an optimal sampling strategy for meropenem in febrile neutropenics.

Ariano RE, Zelenitsky SA, Nyhlén A, Sitar DS.

J Clin Pharmacol. 2005 Jul;45(7):832-5.

PMID:
15951473
22.

Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia.

Zelenitsky SA, Iacovides H, Ariano RE, Harding GK.

Diagn Microbiol Infect Dis. 2005 Jan;51(1):39-43.

PMID:
15629227
23.

Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.

Ariano RE, Nyhlén A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA.

Ann Pharmacother. 2005 Jan;39(1):32-8. Epub 2004 Dec 14.

PMID:
15598967
24.

Effect of antibiotic sequence on combination regimens against Pseudomonas aeruginosa in a multiple-dose, in vitro infection model.

Zelenitsky SA, Iacovides H, Harding GK, Ariano RE.

Diagn Microbiol Infect Dis. 2004 May;49(1):67-70.

PMID:
15135504
25.

Peritoneal fluid titer test for peritoneal dialysis-related peritonitis.

Strijack C, Harding GK, Ariano RE, Zelenitsky SA.

Antimicrob Agents Chemother. 2004 May;48(5):1719-26.

26.

Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.

Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE.

J Antimicrob Chemother. 2003 Oct;52(4):668-74. Epub 2003 Sep 1.

PMID:
12951354
27.

AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.

Zelenitsky SA, Ariano RE, Iacovides H, Sun S, Harding GK.

J Antimicrob Chemother. 2003 Apr;51(4):905-11. Epub 2003 Mar 13.

PMID:
12654762
28.

Bayesian pharmacokinetic analysis of a gentamicin nomogram in neonates: a retrospective study.

Ariano RE, Sitar DS, Davi M, Zelenitsky SA.

Curr Ther Res Clin Exp. 2003 Mar;64(3):178-88. doi: 10.1016/S0011-393X(03)00022-5.

29.

Challenging the current treatment paradigm for methicillin-resistant Staphylococcus epidermidis peritonitis in peritoneal dialysis patients.

Ariano RE, Franczuk C, Fine A, Harding GK, Zelenitsky SA.

Perit Dial Int. 2002 May-Jun;22(3):335-8.

PMID:
12227390
30.

Antibiotic pharmacodynamics in surgical prophylaxis: an association between intraoperative antibiotic concentrations and efficacy.

Zelenitsky SA, Ariano RE, Harding GK, Silverman RE.

Antimicrob Agents Chemother. 2002 Sep;46(9):3026-30.

31.

An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters.

Vercaigne LM, Zelenitsky SA, Findlay I, Bernstein K, Penner SB.

J Antimicrob Chemother. 2002 Apr;49(4):693-6.

PMID:
11909847
33.
34.
35.

Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.

Zelenitsky SA, Karlowsky JA, Hoban DJ, Kabani A, Zhanel GG.

Chemotherapy. 1998 Jan-Feb;44(1):1-6.

PMID:
9444401
36.

In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species.

Karlowsky JA, Harding GA, Zelenitsky SA, Hoban DJ, Kabani A, Balko TV, Turik M, Zhanel GG.

Antimicrob Agents Chemother. 1997 Nov;41(11):2576-8.

37.

Altered denA and anr gene expression in aminoglycoside adaptive resistance in Pseudomonas aeruginosa.

Karlowsky JA, Hoban DJ, Zelenitsky SA, Zhanel GG.

J Antimicrob Chemother. 1997 Sep;40(3):371-6.

PMID:
9338489
38.

In vitro antifungal activity of BMS-181184 against systemic isolates of Candida, Cryptococcus, and Blastomyces species.

Karlowsky JA, Zhanel GG, Balko TV, Zelenitsky SA, Kabani AM, Hoban DJ.

Diagn Microbiol Infect Dis. 1997 Aug;28(4):179-82.

PMID:
9327245
39.

Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.

Zelenitsky SA, Karlowsky JA, Zhanel GG, Hoban DJ, Nicas T.

Antimicrob Agents Chemother. 1997 Jun;41(6):1407-8. No abstract available.

40.

Aminoglycoside adaptive resistance.

Karlowsky JA, Zelenitsky SA, Zhanel GG.

Pharmacotherapy. 1997 May-Jun;17(3):549-55. Review.

PMID:
9165557
41.

In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.

Zhanel GG, Karlowsky JA, Harding GA, Balko TV, Zelenitsky SA, Friesen M, Kabani A, Turik M, Hoban DJ.

Antimicrob Agents Chemother. 1997 Apr;41(4):863-5.

42.

Phenazopyridine in urinary tract infections.

Zelenitsky SA, Zhanel GG.

Ann Pharmacother. 1996 Jul-Aug;30(7-8):866-8. Review. No abstract available.

PMID:
8826573
43.

Implementation of an aminoglycoside order review process in a central dispensary.

Zelenitsky SA, Richard A.

Can J Hosp Pharm. 1993 Dec;46(6):269-74. No abstract available.

PMID:
10131345
44.

Ketorolac (Toradol): a marketing phenomenon.

Ariano RE, Zelenitsky SA.

CMAJ. 1993 May 15;148(10):1686-8. No abstract available.

Supplemental Content

Loading ...
Support Center